Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code

YE Linlan, HE Chunhui, ZHU Xuting, LI Xia. Hexokinase inhibitor 2-deoxyglucose combined with phenformin induces cell apoptosis of triple-negative breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2022, 40(3): 248-253. doi: 10.12206/j.issn.1006-0111.202103045
Citation: ZHOU Chenjian, ZHAO Langhuan, HU Guoxin. Study on pharmacokinetics of pazopanib in rats[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(4): 346-349. doi: 10.3969/j.issn.1006-0111.2017.04.014

Study on pharmacokinetics of pazopanib in rats

doi: 10.3969/j.issn.1006-0111.2017.04.014
  • Received Date: 2016-12-19
  • Rev Recd Date: 2017-02-17
  • Objective To develop a UPLC-MS method for the determination of pazopanib in rat plasma, and study the pharmacokinetics of pazopanib in rats. Methods The effective UPLC MS/MS separation of the examined compounds was applied on an Acquity BEH C18 column with a gradient mobile phase system. AB Sciex QTRAP 5500 triple quadruple mass spectrometer equipped with an electrospray ionization (ESI) interface was used for mass spectrometric detection. The MRM transitions of m/z 438.3→357.2 and m/z 285.2→193.1 were used to quantify for pazopanib and ISTD, respectively; 6 rats were given 80 mg/kg pazopanib intragastric administration. Blood samples were collected from the tail vein at different point after administration. The concentration of pazopanib in plasma was detected by the UPLC-MS methods. The pharmacokinetics parameters were analyzed by DAS program. Results Pazopanib and ISTD were eluted at 1.10 and 1.37 min respectively. Excellent liner relationship was obtained from the range of 0.25 μg/ml to 40.00 μg/ml (r=0.999 2). The intra-day RSD were 6.17%, 2.73% and 2.54% and inter-day RSD were 7.56%, 5.98% and 2.84% respectively at three concentrations (0.50, 10.00, 30.00 μg/ml), the recoveries were (78.4±4.8)%, (85.9±3.5)% and (81.1±4.2)% respectively, the Matrix effect were (106.7±5.3) %, (101.3±6.7) % and (97.6±4.4) % respectively at three concentrations (0.50, 10.00, 30.00 μg/ml); 6 rats were given 80 mg/kg pazopanib intra-gastric administration. The main pharmacokinetics parameters of pazopanib were as following: cmax (20.22±1.95) μg/ml,tmax (1.75±0.76) h,t1/2 (7.35±2.31) h,AUC0-t (213.16±39.92) μg·h/L,AUC0-∞ (215.79±39.84) μg·h/L,Vd (4.10±1.78) L/kg,CL (0.38±0.07) L/h. Conclusion The method was simple, rapid, accurately,which could be used to determine the pazopanib concentration in rat plasma and study on its pharmacokinetics. Pazopanib was fitted to the first-order elimination kinetics in rats.
  • [1] Ranieri G, Mammì M, Donato Di Paola E,et al. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: A new treatment for metastatic soft tissue sarcoma[J]. Crit Rev Oncol Hematol,2014,89(2):322-329.
    [2] Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor[J].Oncologist,2010,15(6):539-547.
    [3] Motzer RJ,Hutson TE,Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma[J]. N Engl J Med,2013,369(8):722-731.
    [4] Welsh SJ,Fife K. Pazopanib for the treatment of renal cell carcinoma[J]. Future Oncol,2015,11(8):1169-1179.
    [5] Dziadosz M,Lessig R,Bartels H. HPLC-DAD protein kinase inhibitor analysis in human serum[J].J Chromatogr B Analyt Technol Biomed Life Sci,2012,893-894:77-81.
    [6] Minocha M, Khurana V, Mitra AK. Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS)[J]. J Chromatogr B Analyt Technol Biomed Life Sci,2012, 901:85-92.
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-04012345Highcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 90.8 %FULLTEXT: 90.8 %META: 7.2 %META: 7.2 %PDF: 1.9 %PDF: 1.9 %FULLTEXTMETAPDFHighcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 29.2 %其他: 29.2 %其他: 0.3 %其他: 0.3 %China: 1.1 %China: 1.1 %Taiwan, China: 0.3 %Taiwan, China: 0.3 %[]: 0.3 %[]: 0.3 %上海: 0.3 %上海: 0.3 %六安: 0.3 %六安: 0.3 %加利福尼亚州: 0.6 %加利福尼亚州: 0.6 %北京: 18.7 %北京: 18.7 %合肥: 1.1 %合肥: 1.1 %恩施: 0.3 %恩施: 0.3 %成都: 0.3 %成都: 0.3 %湖州: 0.8 %湖州: 0.8 %芒廷维尤: 29.2 %芒廷维尤: 29.2 %芝加哥: 0.3 %芝加哥: 0.3 %西宁: 15.9 %西宁: 15.9 %运城: 0.3 %运城: 0.3 %长春: 0.3 %长春: 0.3 %长沙: 0.3 %长沙: 0.3 %青岛: 0.3 %青岛: 0.3 %其他其他ChinaTaiwan, China[]上海六安加利福尼亚州北京合肥恩施成都湖州芒廷维尤芝加哥西宁运城长春长沙青岛Highcharts.com
  • Cited by

    Periodical cited type(3)

    1. 杨凌,韩杰,谢小中,金万清,彭清林. 基于巨噬细胞及其相关通路探讨骨坚散干预激素性股骨头坏死作用机制. 辽宁中医药大学学报. 2025(02): 113-118 .
    2. 刘奇,章越,盛燕,胡云莉,姜慧洁,慎凯峰,姜艳,陈承守,周丹英. 基于层次分析法-熵权法-独立性权法结合正交设计法优选胃病1号提取工艺. 中国现代应用药学. 2023(21): 2998-3004 .
    3. 陆玫霖,潘其明,王宝林,何宇铭,黄婉凤,陈明,钟国跃,杨世林,高红伟. 山鸡椒的化学成分、药理活性及临床应用研究进展. 中草药. 2022(17): 5565-5581 .

    Other cited types(2)

通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Article Metrics

Article views(4288) PDF downloads(638) Cited by(5)

Related
Proportional views

Study on pharmacokinetics of pazopanib in rats

doi: 10.3969/j.issn.1006-0111.2017.04.014

Abstract: Objective To develop a UPLC-MS method for the determination of pazopanib in rat plasma, and study the pharmacokinetics of pazopanib in rats. Methods The effective UPLC MS/MS separation of the examined compounds was applied on an Acquity BEH C18 column with a gradient mobile phase system. AB Sciex QTRAP 5500 triple quadruple mass spectrometer equipped with an electrospray ionization (ESI) interface was used for mass spectrometric detection. The MRM transitions of m/z 438.3→357.2 and m/z 285.2→193.1 were used to quantify for pazopanib and ISTD, respectively; 6 rats were given 80 mg/kg pazopanib intragastric administration. Blood samples were collected from the tail vein at different point after administration. The concentration of pazopanib in plasma was detected by the UPLC-MS methods. The pharmacokinetics parameters were analyzed by DAS program. Results Pazopanib and ISTD were eluted at 1.10 and 1.37 min respectively. Excellent liner relationship was obtained from the range of 0.25 μg/ml to 40.00 μg/ml (r=0.999 2). The intra-day RSD were 6.17%, 2.73% and 2.54% and inter-day RSD were 7.56%, 5.98% and 2.84% respectively at three concentrations (0.50, 10.00, 30.00 μg/ml), the recoveries were (78.4±4.8)%, (85.9±3.5)% and (81.1±4.2)% respectively, the Matrix effect were (106.7±5.3) %, (101.3±6.7) % and (97.6±4.4) % respectively at three concentrations (0.50, 10.00, 30.00 μg/ml); 6 rats were given 80 mg/kg pazopanib intra-gastric administration. The main pharmacokinetics parameters of pazopanib were as following: cmax (20.22±1.95) μg/ml,tmax (1.75±0.76) h,t1/2 (7.35±2.31) h,AUC0-t (213.16±39.92) μg·h/L,AUC0-∞ (215.79±39.84) μg·h/L,Vd (4.10±1.78) L/kg,CL (0.38±0.07) L/h. Conclusion The method was simple, rapid, accurately,which could be used to determine the pazopanib concentration in rat plasma and study on its pharmacokinetics. Pazopanib was fitted to the first-order elimination kinetics in rats.

YE Linlan, HE Chunhui, ZHU Xuting, LI Xia. Hexokinase inhibitor 2-deoxyglucose combined with phenformin induces cell apoptosis of triple-negative breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2022, 40(3): 248-253. doi: 10.12206/j.issn.1006-0111.202103045
Citation: ZHOU Chenjian, ZHAO Langhuan, HU Guoxin. Study on pharmacokinetics of pazopanib in rats[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(4): 346-349. doi: 10.3969/j.issn.1006-0111.2017.04.014
Reference (6)

Catalog

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return